Hepatitis B Virus Reactivation After Switch to Cabotegravir/Rilpivirine in Patient with Low Hepatitis B Surface Antibody

• DOI: 10.3201/eid3008.240019
• Publication Date: 2024-07-30T03:09:39Z
• Authors: Eisuke Adachi; Ayako Sedohara; Kotaro Arizono; Kazuaki Takahashi; Amato Otani; Yoshiaki Kanno; Makoto Saito; Michiko Koga; Hiroshi Yotsuyanagi
• Keywords: Male; Hepatitis B virus; Pyridones; Anti-HIV Agents; antiretroviral therapy; HIV Infections; Infectious and parasitic diseases; RC109-216; Diketopiperazines; 03 medical and health sciences; HBV; Humans; Hepatitis B Antibodies; 0303 health sciences; Hepatitis B Surface Antigens; cabotegravir; R; Dispatch; HIV; Middle Aged; Hepatitis B; Pyrimidines; Medicine; Virus Activation; hepatitis B; hepatitis B virus

A patient in Japan with HIV began antiretroviral therapy because of acute hepatitis B virus (HBV) 15 years ago, with low hepatitis B surface antibody, and experienced breakthrough HBV reactivation 4 months after switching from bictegravir/emtricitabine/tenofovir alafenamide to cabotegravir/rilpivirine. An immune escape mutation, E164V, was identified in the isolated HBV DNA.